Philippines

Population 2017: 105 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>26 (23–31)</td>
<td>25 (22–29)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.38 (0–3.3)</td>
<td>0.36 (0–3.1)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>581 (326–909)</td>
<td>554 (311–866)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>7 (2.9–13)</td>
<td>6.6 (2.8–12)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>27 (12–47)</td>
<td>26 (12–45)</td>
</tr>
</tbody>
</table>

Estimated TB incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>34 (9.2–59)</td>
<td>37 (10-65)</td>
<td>71 (31–112)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>130 (36–241)</td>
<td>371 (100-641)</td>
<td>510 (222–798)</td>
</tr>
</tbody>
</table>

TB case notifications, 2017

Total cases notified: 328 773
Total new and relapse: 317 266
- % with known HIV status: 24%
- % pulmonary: 98%
- % bacteriologically confirmed among pulmonary: 39%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017: 55% (35–97)
TB patients facing catastrophic total costs, 2017: 35%
TB case fatality ratio (estimated mortality/estimated incidence), 2017: 0.05 (0.03–0.06)

TB/HIV care in new and relapse TB patients, 2017

Patients with known HIV-status who are HIV-positive: 1 335 (2%)
- on antiretroviral therapy: 1 185 (89%)

Drug-resistant TB care, 2017

Estimated MDR/RR-TB cases among notified pulmonary TB cases: 20 000 (18 000–22 000)
Estimated % of TB cases with MDR/RR-TB: 2.6% (1.9–3.4) 28% (27–28)
% notified tested for rifampicin resistance: 19% 83% 93 058

Laboratory-confirmed cases

Patients started on treatment ****

MDR/RR-TB: 6 438, XDR-TB: 15
MDR/RR-TB: 5 623, XDR-TB: 16

Treatment success rate and cohort size

New and relapse cases registered in 2016: 91% 332 308
Previously treated cases, excluding relapse, registered in 2016: 80% 10 097
HIV-positive TB cases registered in 2016: 82% 898
MDR/RR-TB cases started on second-line treatment in 2015: 54% 3 851
XDR-TB cases started on second-line treatment in 2015: 33% 9

TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment: 57%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 12% (11–13)

TB financing, 2018

National TB budget (US$ millions): 160
Funding source: 37% domestic, 21% international, 42% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-05-26 Data: www.who.int/tb/data